Occurence of 17p Deletion with Blast Transformation in Idiopathic Myelofibrosis Treated with Hydroxyurea.
- Author:
Jung Sook HA
1
;
Nam Hee RYOO
;
Jae Ryong KIM
;
Dong Suk JEON
Author Information
1. Department of Diagnostic Laboratory Medicine, Dong-San Medical Center, College of Medicine, Keimyung University, Daegu, Korea. ksksmom@dsmc.or.kr
- Publication Type:Case Report
- Keywords:
l7p deletion;
Hydroxyurea;
Idiopathic myelofibrosis
- MeSH:
Hematologic Diseases;
Hydroxyurea*;
Leukemia, Myeloid, Acute;
Lymphocyte Activation*;
Myelodysplastic Syndromes;
Neutrophils;
Primary Myelofibrosis*;
Vacuoles
- From:Korean Journal of Hematology
2004;39(1):46-50
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The recently described '17p deletion syndrome' is a clonal hematologic disease which has characteristic dysgranulopoietic features, such as pseudo-Pelger-Huet hypogranulation and small vacuoles in neutrophils and is strongly associated with p53 mutation. The cases with 17p deletion are seen in 3~4% of myelodysplastic syndrome and acute myelogenous leukemia and about 30% of them are therapy-related. Hydroxyurea, which is considered to have relatively low leukemogenic potential, has therefore been widely used in chronic myeloproliferative disease. But the recent study has found that hydroxyurea administration is a considerable risk for later leukemic transformation and is closely associated with development of 17p deletion. We report one case of idiopathic myelofibrosis which developed 17p deletion with blast increment after hydroxyurea therapy for 3 years.
